News & Updates

Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.

A single dose of FINLAY-FR-1A, a recombinant d-RBD*-based COVID-19 vaccine, strengthens pre-existing natural immunity in patients who have recovered from asymptomatic, mild or moderate COVID-19, and has an excellent safety profile, a phase IIa/b study has shown.

Reslizumab, a biologic targeting interleukin(IL)-5, reduced severe asthma exacerbation rate and oral corticosteroid (OCS) use in individuals with severe eosinophilic asthma, according to a real-world study using patient-level data from RAPSODI*.

Treatment with sotrovimab does not appear to confer protection against severe forms of COVID-19 in a setting dominated by the Omicron BA.2 subvariant, a study has found.

Children suffering from bronchiectasis may benefit from a play-based therapeutic exercise regimen, which results in better fitness and fundamental movement skill (FMS), according to a recent pilot trial.

Older adults who receive a high-dose quadrivalent influenza vaccine have a 49 percent reduced risk of death and a 64 percent reduced risk of hospitalization for influenza or pneumonia compared with those who receive a standard-dose vaccine, results of the DANFLU-1 study showed.

In the phase III SPRINTER trial, inhaled interferon-beta-1a (IFN-β1a) showed encouraging signals for preventing disease progression or death in hospitalized COVID-19 patients.